The Committee for Veterinary Medicinal Products (CVMP) met on 16-18 June 2026. Alongside its usual product decisions, the Committee advanced two guideline reviews for sponsors working on vaccines and other immunological products.
Among the most notable, were two concept papers adopted for release to public consultation, both centred on immunological veterinary medicinal products (IVMPs).
The first proposes a revision of the Guideline for authorising IVMPs under ‘exceptional circumstances’, a pathway used when based on animal or public health reasons exemptions to a full data packages may be granted, informed by real experience from the first applications filed under Article 25 of Regulation (EU) 2019/6. The intended revision aims to improve clarification of data requirements.
The second concept paper targets a narrow but practical problem, in terms of how developers can replace an established master seed with a new one of the same origin without re-running an entire authorisation. It is intended to revise the existing guidance and provide better clarification on data requirements.
Both concept papers are open for a three-month consultation period until 30 September, giving industry an opportunity to shape the final wording. Comments can be submitted via the listed template to vet-guidelines@ema.europa.eu.
The meeting’s more immediate impact is on the shelf. The standout news for companion animal sponsors is a cluster of positive opinions across the Nobivac NXT line, including HCPChFeLV, FeLV, and HCPFeLV, extending feline vaccine coverage against core viral and bacterial threats, and one negative opinion for Scovella (velagliflozin), intended for insulin dysregulated horses and ponies. The Committee also recommended to extend the exceptional circumstances authorisation of Innovax ND-H5, an avian influenza vaccine, for one year.
Beyond individual products, the Committee adopted a strategic stock-take on antimicrobial resistance, reviewing five years of activity and setting the direction for future work under EMANS 2028’s One Health approach. This new overview document is yet to be published. In the meantime, the CVMP Strategy on Antimicrobials 2021-2025 that it builds on remains publicly available for anyone tracking how AMR policy is shaping veterinary drug development requirements.
Finally, on the pharmacovigilance side, the annual VeDDRA terminology update, tracked through EudraVigilance Veterinary, is due for implementation from 1 October 2026.
A full account of the discussions is available in European Medicines Agency (EMA) meeting highlights.
